NEW YORK (GenomeWeb) – SomaLogic notched another placement for its SomaScan assay platform, announcing this week that the University of Oxford would install a system as part of a larger collaboration between the two parties.

According to John Bell, professor of medicine at Oxford and chairman of the UK's Office for Strategic Coordination of Health Research, Oxford researchers will use the SomaScan platform for work on protein biomarkers for conditions including inflammatory diseases, Alzheimer's, and cancer.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.